Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index &#8805;27 kg/m<sup>2</sup>.

Mathieu, Chantal; Dandona, Paresh; Birkenfeld, Andreas L; Hansen, Troels Krarup; Iqbal, Nayyar; Xu, John; Repetto, Enrico; Scheerer, Markus Florian; Thoren, Fredrik; Phillip, Moshe

Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m².

Mathieu, Chantal; Dandona, Paresh; Birkenfeld, Andreas L; Hansen, Troels Krarup; Iqbal, Nayyar; Xu, John; Repetto, Enrico; Scheerer, Markus Florian; Thoren, Fredrik; Phillip, Moshe.

Afiliação

Mathieu C; Clinical and Experimental Endocrinology, UZ Gasthuisberg, University of Leuven, Leuven, Belgium.
Dandona P; State University of New York at Buffalo, Williamsville, New York, USA.
Birkenfeld AL; Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Centre Munich, University of Tübingen, Tübingen, Germany.
Hansen TK; German Center for Diabetes Research (DZD), Tübingen, Germany.
Iqbal N; Department of Internal Medicine, Division of Endocrinology, Diabetology and Nephrology, Eberhard Karls University Tübingen, Tübingen, Germany.
Xu J; Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
Repetto E; Late-stage Development Cardiovascular, Renal and Metabolism, AstraZeneca, Gaithersburg, Maryland, USA.
Scheerer MF; Late-stage Development Cardiovascular, Renal and Metabolism, AstraZeneca, Gaithersburg, Maryland, USA.
Thoren F; Global Medical Affairs, AstraZeneca, Gaithersburg, Maryland, USA.
Phillip M; Diabetes Medical Department, AstraZeneca, Wedel, Germany.

Diabetes Obes Metab ; 22(11): 2151-2160, 2020 11.

Article em En | MEDLINE | ID: mdl-32691513

Assuntos

Diabetes Mellitus Tipo 1; Compostos Benzidrílicos; Índice de Massa Corporal; Diabetes Mellitus Tipo 1/complicações; Diabetes Mellitus Tipo 1/tratamento farmacológico; Diabetes Mellitus Tipo 1/epidemiologia; Glucosídeos/efeitos adversos; Humanos; Hipoglicemiantes/efeitos adversos

Palavras-chave

BMI; DEPICT; DKA; HbA1c; T1D; benefit/risk; body weight; dapagliflozin; type 1 diabetes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google